AXUMIN (18F-Fluciclovine), radiopharmaceutical

High clinical benefit in the detection of prostate cancer recurrence in the event of suspected recurrence after first-line treatment, though no demonstrated clinical added value in the therapeutic strategy.

• AXUMIN has been granted marketing authorisation for positron emission tomography (PET) imaging to detect recurrent prostate cancer in the event of suspected recurrence based on a renewed increase in serum prostate-specific antigen (PSA) concentrations after first-line curative treatment.

• The poor methodological quality of the data available, along with the lack of comparison to ¹⁸F-fluorocholine, prevent any conclusions from being drawn concerning any possible diagnostic benefit of ¹⁸F-fluorocholine-based PET.